Full Text View
Tabular View
No Study Results Posted
Related Studies
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
This study has been completed.
Study NCT00371735   Information provided by GlaxoSmithKline
First Received: September 1, 2006   Last Updated: May 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Malaria
Additional conditions recognized in this trial
Malaria, Falciparum
More general conditions related to this trial
Coccidiosis
Parasitic Diseases
Protozoan Infections
Interventions listed in this trial
chlorproguanil-dapsone-artesunate
chlorproguanil-dapsone
Additional drug interventions recognized in this trial
Artesunate
Chloroguanide
Chlorproguanil
Dapsone
More general drug interventions related to this trial
Amebicides
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antimetabolites
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services